The effects of denosumab compared with oral bisphosphonates (BP) in patients with RA complicated with osteoporosis on the progression of structural damage, BMD and disease activity.

Trial Profile

The effects of denosumab compared with oral bisphosphonates (BP) in patients with RA complicated with osteoporosis on the progression of structural damage, BMD and disease activity.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2016

At a glance

  • Drugs Denosumab (Primary) ; Bisphosphonates
  • Indications Osteoporosis; Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms Two Birds
  • Most Recent Events

    • 03 Aug 2016 Status changed from recruiting to discontinued.
    • 17 Aug 2015 Planned End Date is 31 Mar 2017, according to University Hospital Medical Information Network - Japan record.
    • 08 Aug 2014 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top